Source: University of Minnesota It’s a researcher’s dream: a simple, noninvasive test to detect life-threatening cancer, heart disease, or other maladies while they’re still treatable. A team of University of Minnesota researchers is in hot pursuit of that goal, using one of the simplest means imaginable: testing spit. They’ve discovered that conditions such as breast [...]
Continue reading...Tuesday, January 10, 2012
Source: www.thetelegraphandargus.co.uk/ Author: staff Mouth cancer patients in Bradford will be the first in the world to try a new battery-powered gum shield that could end the misery of a dry mouth. The pacemaker device fits over the lower teeth and uses minor, painless, electric shocks to trigger saliva production. A dry mouth is a [...]
Continue reading...Thursday, December 22, 2011
Source: www.proactiveinvestors.com Author: Amanda Brandon Vigilant Biosciences is a privately held medical technology company based in Norcross, Georgia focused on improving healthcare products to improve patient care. Their most recent research efforts center on early oral cancer detection. In the United States, approximately 37,000 people will be diagnosed with oral cancer this year and its [...]
Continue reading...Thursday, December 22, 2011
Soure: www.curetoday.com/ Author: Lacey Meyer Dentists advise resolving tooth and gum issues before starting cancer treatment. Bettye Davis admits she has never had very good teeth. But when she received a diagnosis of salivary gland cancer, she was surprised that her oncologist recommended she visit a dentist before beginning radiation treatments to her jaw. “When [...]
Continue reading...Sunday, November 6, 2011
Source: http://www.sciencenews.org Author: Susan Galdos Rinse and spit. Someday soon, doctors may join dentists in issuing these simple instructions. And before leaving the office, you might know whether you’re at risk for oral cancer. Additional tests on that same ptui may reveal whether you show signs of certain other cancers or diseases such as diabetes [...]
Continue reading...Friday, September 2, 2011
Source: www.healthnewsdigest.com Author: press release Researchers at The Ohio State University Comprehensive Cancer Center have developed a medicated oral patch that allows a chemoprevention drug to release directly into precancerous lesions in the mouth over an extended time. The study evaluated the drug fenretinide, a synthetic derivative of vitamin A that has highly promising anti-cancer [...]
Continue reading...Friday, February 4, 2011
Source: www.thelancet.com Authors: Dr Christopher M Nutting FRCR et al. Background: Xerostomia is the most common late side-effect of radiotherapy to the head and neck. Compared with conventional radiotherapy, intensity-modulated radiotherapy (IMRT) can reduce irradiation of the parotid glands. We assessed the hypothesis that parotid-sparing IMRT reduces the incidence of severe xerostomia. Methods: We undertook [...]
Continue reading...Thursday, January 13, 2011
Source: jjco.oxfordjournals.org Authors: Etsushi Tomitaka et al. Objective: To evaluate longitudinal changes in parotid volumes and saliva production over 2 years after 30 Gy irradiation. Methods: We retrospectively evaluated 15 assessable patients treated for advanced oral cancer. Eligibility criteria were a pathologic diagnosis of squamous cell carcinoma, preoperative radiation therapy with a total dose of [...]
Continue reading...Tuesday, August 31, 2010
Source: Oral and Maxillofacial Pathology doi:10.1016 Author: Mark W. Lingen, DDS, PhD Section Editor, Oral and Maxillofacial Pathology Head and neck squamous cell carcinoma (HNSCC) is the 6th most common malignancy in the world today.1 Despite numerous advances in treatment, the 5-year survival rate has remained modest. This poor outcome is due to several factors, [...]
Continue reading...Sunday, August 1, 2010
Source: www.nyu.edu/dental/news Author: staff The NYU College of Dentistry has received an anonymous gift in the amount of $3.5 million to support the oral cancer research, treatment, and training initiatives of Dr. Brian L. Schmidt, the newly appointed Director of the Bluestone Center for Clinical Research. These initiatives center on early detection, pain control, and [...]
Continue reading...
Wednesday, February 1, 2012
0 Comments